Biocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges impacting the company's financials. However, core businesses demonstrated growth. The company successfully integrated its biosimilars and generics operations. This strategic move aims to enhance scale and market reach. Biocon is now focused on improving profitability and creating long-term value for shareholders.